Understanding breast cancer: a complex disease with a growing arsenal of treatments

3D graphic showing a tumor and individual tumor cells spreading from it
3D graphic showing a tumor and individual tumor cells spreading from it
Logo

Understanding breast cancer: a complex disease with a growing arsenal of treatments

Breast cancer is one of the most common cancers worldwide, affecting millions of people each year. While it predominantly impacts women, it can also occur in men, making it a disease everyone should be aware of. Understanding breast cancer – its causes, symptoms, and treatment options – can empower individuals to take charge of their health and promote early detection.

In this blog post we explore the different types and risk factors for breast cancer, markers that can be used for its investigation, and recent therapeutic developments shaping the future of breast cancer research.

Read time: 5–10 minutes

This information is intended for biological researchers and should not be viewed as advice on medical treatments for breast cancer.

Check out our blog and get up to speed on the latest in breast cancer research

What is breast cancer?

Breast cancer is a type of cancer that originates in the cells of the breast. It occurs when abnormal cells grow uncontrollably, forming a tumor that can invade surrounding tissues or spread to other parts of the body (metastasis). Most breast cancers begin in the milk-producing glands (lobules) or the ducts that carry milk to the nipple.

What types of breast cancer are there?

Comprehensive staining of ductal breast carcinoma with REAplex Immuno-oncology Core

Breast cancer is a diverse disease with multiple subtypes, each defined by unique molecular characteristics, prognosis, and treatment responses. The main types of breast cancer include:1

  • Ductal carcinoma in situ: A non-invasive cancer where abnormal cells are confined to the milk ducts.
  • Invasive ductal carcinoma: The most common type, where cancer cells spread beyond the ducts into surrounding tissue.
  • Invasive lobular carcinoma: Cancer that begins in the lobules and can spread.
  • Triple-negative breast cancer: An aggressive form that lacks expression of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2). Accounts for about 10-15% of all breast cancers.
  • HER2-positive breast cancer: Driven by overexpression of the HER2 protein, which promotes cancer cell growth.

Icon showing a shining lightbulb with an exclamaiton mark on it

Did you know?

Naked mole rats, a species of rodent, rarely develop cancer. These animals produce a specific type of sugar (high-molecular-mass hyaluronan) that prevents their cells from clumping together in a way that could lead to tumors.2 In addition, elephants, despite having many more cells than humans, have an incredibly low cancer rate. They have around 20 copies of the TP53 gene, which is known to suppress tumors, while humans only have one copy.3

What are the risk factors for breast cancer?

Breast cancer develops due to a combination of genetic, environmental, and lifestyle factors. While some risk factors can’t be controlled, others can be addressed to lower the likelihood of developing the disease.4

  • Age: The risk increases with age, particularly after 50.
  • Family history: A family history of breast cancer increases risk, especially if close relatives were diagnosed at a young age.
  • Genetic mutations: Inherited mutations, such as BRCA1 and BRCA2, significantly raise the risk of breast cancer.
  • Hormonal factors: Early menstruation (before age 12) or late menopause (after age 55) as well as hormone replacement therapy (HRT).
  • Lifestyle factors: including alcohol consumption, obesity (particularly after menopause), and lack of physical activity.

What markers can be used to investigate breast cancer?

Breast cancer biomarkers are molecules found in tumor cells, tissues, or blood that provide important information for diagnosis, prognosis, and treatment planning. Here are key markers commonly associated with breast cancer:

  • Hormone receptors: ER and PR indicate tumors that grow in response to estrogen and progesterone respectively. ER-positive breast cancers are often treated with hormone therapy, while PR status helps guide hormone therapy decisions.5,6
  • HER2: HER2 is a protein that plays a key role in cell growth, division, and repair. It is encoded by the ERBB2 gene, which regulates cell signaling pathways. HER2-positive cancers have an overexpression of the HER2 protein, leading to aggressive tumor growth. Targeted therapies like trastuzumab (Herceptin) are used to treat HER2-positive breast cancers.7
  • Melanoma-associated antigen A1 (MAGE-A1): MAGE-A1 is a tumor-associated antigen of the cancer/testis family, usually silenced in healthy somatic cells. It is aberrantly expressed in various cancers, including breast cancer. MAGE-A1 has immunogenic properties, making it a target for cancer immunotherapy approaches, such as T cell–based therapies.8
  • Nuclear antigen Ki-67: Ki-67 is a marker of cell proliferation. High Ki-67 levels indicate rapidly dividing tumor cells, which may suggest more aggressive cancer and influence treatment decisions.9
  • BRCA1 and BRCA2 mutations: BRCA1 and BRCA2 are genes that produce proteins responsible for repairing damaged DNA. These genes are known as tumor suppressor genes because they help prevent uncontrolled cell growth, which can lead to cancer.10
  • Tumor protein 53 (p53): p53 is a tumor suppressor protein. Mutations in p53 are associated with more aggressive breast cancers and poorer prognosis.11
  • Cyclin D1: Cyclin D1 is a protein involved in cell cycle regulation. Overexpression can indicate more aggressive tumor growth.12
  • Cancer antigen 15-3 (CA 15-3) and cancer antigen 27-29 (CA 27-29): CA 15-3 and CA 27-29 are fragments of the MUC1 glycoprotein. MUC1 is often overexpressed in breast cancer and abnormally glycosylated, leading to loss of cell polarity, tumor progression, and immune evasion.13
  • Carcinoembryonic antigen (CEA): A blood marker that can help monitor advanced breast cancer.14
  • Programmed death-ligand 1 (PD-L1): PD-L1 is a protein that helps cancer cells evade the immune system by inhibiting T-cell activity. It is used as a marker to identify tumors that may respond to immunotherapy, particularly in triple-negative breast cancer.15

Icon showing a publication
Research highlight

Read more about how the gentleMACS® Tissue Dissociator and Mouse Tumor Dissociation Kit contribute to research into BRCA1 and BRCA2 deficiency on immune checkpoint blockade therapy outcomes.

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Samstein, R. et al. (2021) Nat Cancer. 1(12):1188-1203. | Read article

Icon showing a publication
Research highlight

Read more about how the MACS® Separator Columns, magnetic MicroBeads, and FcR blocking reagent contribute to research into the tumor microenvironment in breast cancer.

Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth
Perdrix-Rosell, A. et al. (2022) Cancer Lett. 544:215800. | Read article

What advances have been made in breast cancer treatment?

Cancer treatment has evolved significantly in recent decades, moving from traditional approaches like surgery, hormone therapy, and chemotherapy to more targeted and personalized therapies.

Here's an overview of two particularly promising key treatment options:

  • Immunotherapy: This groundbreaking approach harnesses the body’s immune system to fight cancer. Drugs like checkpoint inhibitors (e.g., PD-1, PD-L1, and CTLA-4 inhibitors) and engineered T-cell therapy (CAR T–cell therapy and TCR T–cell therapy) help the immune system recognize and attack cancer cells more effectively.16
    • Checkpoint inhibitors block proteins on cancer cells that prevent immune cells from attacking them. Examples include PD-L1 inhibitor Atezolizumab (Tecentriq) and PD-1 inhibitor Pembrolizumab (Keytruda), both approved for triple-negative breast cancer.17
    • CAR T–cell therapy involves modifying a patient's T cells to better recognize and destroy cancer. Clinical trials are investigating the use of HER2-targeted CAR T cells, where the T cells are engineered to target and destroy HER2-positive breast cancer cells.18
    • TCR T–cell therapy (T cell–receptor therapy) is an advanced form of immunotherapy that uses genetically modified T cells to target and destroy cancer cells. It is similar to CAR T–cell therapy but focuses on different aspects of how T cells recognize and attack cancer cells.19
    • Cancer vaccines stimulate the immune system to recognize specific proteins expressed by cancer cells, like MUC1 and HER2, which are currently in clinical trials.20
  • Targeted therapy: These treatments target specific molecules involved in cancer cell growth. Drugs like hormone receptor–targeted therapies (e.g., Tamoxifen, Aromatase inhibitors),21 PARP inhibitors (e.g., olaparib, talazoparib),22 AKT inhibitor (e.g. Capivasertib),23 and CDK4/6 inhibitors (e.g., Palbociclib, Ribociclib)24 are designed to target cancer cells while sparing healthy ones, reducing side effects.

What new developments are there in breast cancer research?

Breast cancer research is rapidly evolving, with groundbreaking advancements in early detection, targeted therapies, and personalized medicine offering new hope for patients. Recent studies explore a new understanding of cancer biology and the surrounding tissues, to better target therapies and novel drug combinations that could revolutionize care.

Genetic alterations in healthy breast tissue

Recent studies have discovered that healthy breast tissues can contain cells with genetic changes characteristic of invasive breast cancer, such as aneuploidy and mutations commonly found in cancer. These findings raise concerns about diagnosis accuracy, as such cells could potentially be misdiagnosed as cancerous. This underscores the need for refined diagnostic criteria to distinguish between benign and malignant cells more effectively.

Normal breast tissues harbour rare populations of aneuploid epithelial cells
Lin, Y. et al. (2024) Nature. 636(8043):663-670. | Read article

Neurotransmitters' role in breast cancer

Emerging research indicates that neurotransmitters, such as serotonin and dopamine, significantly influence breast cancer biology. They affect various processes, including the cell cycle, epithelial-mesenchymal transition, and angiogenesis, thereby contributing to cancer progression. Understanding these mechanisms opens avenues for novel therapeutic strategies targeting neurotransmitter pathways.

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions
Jayachandran, P. et al. (2023) Oncogene. 42(9):627-637. | Read article

Metabolic states of dormant breast cancer cells

A review highlights that the metabolic states of dormant breast cancer cells vary depending on the subtype and receptor status. These metabolic shifts are crucial in understanding how dormant cells survive and what triggers their reactivation, which is vital for developing treatments to prevent cancer recurrence.

Recent insights into the effects of metabolism on breast cancer cell dormancy
Bartlome, S. et al. (2022) Br J Cancer. 127(8):1385-1393. | Read article

You have previously chosen International as your location.
What do you want to do?